Tirzepatide (Mounjaro/Zepbound) generally produces greater weight loss than semaglutide (Ozempic/Wegovy) in head-to-head comparisons. The SURPASS trials showed tirzepatide achieving 15-22% body weight reduction, while STEP trials for semaglutide showed 15-17% average weight loss. Tirzepatide's dual mechanism - activating both GLP-1 and GIP receptors - provides enhanced appetite suppression and metabolic effects. However, semaglutide has longer real-world safety data and may be better tolerated by some patients. Both require weekly subcutaneous injections and have similar gastrointestinal side effect profiles.
Find a qualified GLP-1 provider
Compare pricing, clinical oversight, and patient reviews across verified telehealth programs and local clinics.
Compare Providers →Still have questions?
A qualified GLP-1 provider can give you personalized answers based on your medical history and goals.
Get answers to your GLP-1 questions
Weekly updates with the latest research, pricing changes, and expert guidance — delivered to your inbox.
No spam. Unsubscribe anytime.
Ready to start your GLP-1 journey?
Compare verified providers on pricing, medication sourcing, clinical oversight, and patient reviews — all in one place.